US regulatory status: approved.
pharma · ADHD · Idiopathic Hypersomnia · ZVRA
ZEVRA THERAPEUTICS
ZEVRA THERAPEUTICS, INC.
ZEVRA THERAPEUTICS drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boston, USA HQ
2006 Founded
81 Employees
Public company Type
ZVRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2006
- Employees
- 81
- Programs
- 4
- Drugs
- 6
- Patents
- 5
ZEVRA THERAPEUTICS pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ZEVRA THERAPEUTICS drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to ZEVRA THERAPEUTICS in public FDA and regional records.
-
Development asset linked to ZEVRA THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
sodium phenylbutyrate
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Glutamine.
- Target
- Glutamine
- Mechanism
- Glutamine sequestering agent